Sinocare Inc

According to statistics from Securities Times Data Treasure, a total of 13 companies released their 2026 semi-annual reports on August 4. Among them, Jinyu Bio posted the largest profit increase, with net profit up 72.28 percent year-on-year. Jinyu Bio achieved net profit of 104 million yuan and operating revenue of 756 million yuan, up 22.09 percent. WuXi AppTec reported net profit of 11.08 billion yuan, up 29.43 percent, on operating revenue of 28.897 billion yuan, up 38.93 percent. Companies such as Jasan Group, Sinocare, Sihui Fushi, and Wanda Bearing also recorded net profit growth, while seven companies including Jiahuan Technology and Sinodata saw net profit decline year-on-year.

Sinocare has disclosed its 2026 semi-annual report, with net profit attributable to the parent company reaching 221 million yuan in the first half, a year-on-year increase of 22.52%. Total operating revenue for the same period was 2.537 billion yuan, up 12.08% year-on-year. Deducted non-recurring net profit was 210 million yuan, up 32.87% year-on-year. Net cash flow from operating activities was 237 million yuan, down 13.12% year-on-year. At the end of the reporting period, among the top ten tradable shareholders, the third-phase employee stock ownership plan newly entered, replacing Zhao Zhihong from the end of the first quarter. The largest shareholder, Li Shaobo, pledged 76.52 million company shares, accounting for 53.63% of his total holdings.

Sannuo Biotech released its 2026 semi-annual report, achieving operating revenue of 2.537 billion yuan, up 12.08% year-on-year. Net profit attributable to shareholders of the listed company was 221 million yuan, up 22.52% year-on-year. The company plans not to distribute cash dividends, bonus shares, or convert capital reserve into share capital. Second-quarter net profit was 124 million yuan, up 26% quarter-on-quarter from 98 million yuan in the first quarter.

Sinocare announced that its product, the blood glucose and ketone test strip, has passed the special review for Class II innovative medical devices in Hunan Province. The product can quantitatively detect glucose and beta-hydroxybutyrate concentrations in fresh capillary whole blood and venous whole blood, with a single strip capable of simultaneously testing both blood glucose and ketone levels. In addition, the company has made changes to the registration certificates for several medical devices, including blood lipid control solutions and blood lipid test strips, involving product technical requirements, instructions, and packaging specifications, in order to optimize product performance and specifications. In the first quarter of 2026, Sinocare achieved revenue of 1.239 billion yuan and net profit attributable to the parent company of 97.69 million yuan.